PDCD1 and myocarditis: Notably, the coexistence of CTLA-4 and PD-1 disruptions in mice mimics a combined anti-CTLA-4/anti-PD-1 therapy, a risk factor for ICI-associated myocarditis, with CTLA-4-Ig intervention attenuating disease progression [11].